- Patent Title: Mazindol treatment for heroin dependence and substance use disorder
-
Application No.: US16645306Application Date: 2018-09-06
-
Publication No.: US11596622B2Publication Date: 2023-03-07
- Inventor: Alexander C. Zwyer
- Applicant: NLS Pharmaceutics AG
- Applicant Address: CH Stans
- Assignee: NLS Pharmaceutics AG
- Current Assignee: NLS Pharmaceutics AG
- Current Assignee Address: CH Stans
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
- International Application: PCT/IB2018/001138 WO 20180906
- International Announcement: WO2019/058172 WO 20190328
- Main IPC: A61K31/4184
- IPC: A61K31/4184 ; A61P25/36 ; A61K9/24

Abstract:
The present invention relates to mazindol for use in the treatment of dependence and substance use disorder, wherein the substance is an opioid, a composition comprising mazindol and optionally a pharmaceutically acceptable carrier or excipient and/or a diluent, for use in the treatment of substance abuse disorder, wherein the substance is an opioid, and a method of treatment of substance abuse disorder comprising administering mazindol or composition comprising mazindol to a subject, wherein the substance is an opioid. The opioid is preferably heroin.
Public/Granted literature
- US20210161865A1 MAZINDOL TREATMENT FOR HEROIN DEPENDENCE AND SUBSTANCE USE DISORDER Public/Granted day:2021-06-03
Information query
IPC分类: